51 results
AAFP Severity-based approach to treating acne.

#Management #Dermatology #PrimaryCare #Acne #Algorithm #Treatment
#Management #Dermatology ... #PrimaryCare #Acne
Acne treatment algorithm suggested by Gollnick et al - Mild Moderate and Severe Acne
#Management #Dermatology #PrimaryCare
and Severe Acne #Management ... #Dermatology #PrimaryCare
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Macrophage Activation ... Syndrome (MAS) ... manifestation of MAS ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Algorithm for the approach in a man with acute dysuria.

#Diagnosis #Management #PrimaryCare #Algorithm #Male #Man #Dysuria
approach in a man ... #Diagnosis #Management ... #PrimaryCare #Algorithm ... #Male #Man #Dysuria
Global Alliance algorithm to improve outcomes in acne.
†With small nodules (>0.5–1 cm).
‡Consider physical removal of comedones.
§Second
¶There was not consensus ... #Management #Dermatology ... #PrimaryCare #Acne
Proposed Treatment Algorithm for MAS / HLH

#MAS #HLH #Hemophagocytic #Lymphohistiocytosis #Management #Treatment #Algorithm #Hematology
Algorithm for MAS ... / HLH #MAS # ... Lymphohistiocytosis #Management ... Treatment #Algorithm #Hematology
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Diagnosis and Management ... acute leukemia Management ... Myelodysplastic #Syndrome #MDS ... #Diagnosis #Management ... #treatment #hematology
Emphysematous Cystitis
Epidemiology:
 • Usually middle-aged diabetic women
 • Other RF: neurogenic bladder, urinary tract outlet obstruction,
obstruction, chronic UTIs ... May have pneumaturia ... infection, such as ... also important Management ... Cystitis #diagnosis #management
Clinical treatment algorithm for acne. BPO = benzoyl peroxide, clinda = clindamycin, dashed line = optional
and oral zinc may ... #Management #PrimaryCare
Anti-IL6 Agents (Tocilizumab, Siltuximab) in COVID19

IL-6 activates T cells and macrophages, among other cell types (see
activates T cells and macrophages ... x1 (anti-IL6R mAb ... IV x1 (anti-IL6 mAb ... #Pharmacology #Management